- Thiogenesis Therapeutics (TTI) has closed a non-brokered private placement for gross proceeds of $5,309,700
- The company issued 10,619,400 common shares at $0.50 per share
- Net proceeds will be used for the completion of a good lab practices study on absorption with its lead compound TTI-0102, reformulation work on TTI-0102
- Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company
- Thiogenesis Therapeutics Corp. (TTI) opened trading at C$0.64
Thiogenesis Therapeutics (TTI) has closed its previously-announced non-brokered private placement for gross proceeds of $5,309,700.
The company issued 10,619,400 common shares at $0.50 per share.
All securities issued will be subject to a statutory holding period ending March 19, 2023.
The company paid $352,750 in finder’s fees and issued 675,500 in non-transferable finder’s options.
Net proceeds will be used for the completion of a good lab practices study on absorption with its lead compound TTI-0102, reformulation work on TTI-0102, the purchase of inventory and general working capital purposes.
Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company operating through its wholly-owned subsidiary based in San Diego, CA.
Thiogenesis Therapeutics Corp. (TTI) opened trading at C$0.64.
